BRAF Mutation Analysis in Colorectal Cancers and Melanomas

By: | Tags: | Comments: 1 | August 13th, 2016

  • BRAF gene mutation testing is now considered critical in diagnosis, prognosis, treatment, and predicting patient outcome in response to targeted therapy for multiple cancer types.
  • Mutations in BRAF have been reported in up to 60% of cutaneous melanomas and up to 18% of colorectal cancers.
  • About 90% of these mutations are found to be V600E.
  • Treatment with vemurafenib, a highly selective and potent inhibitor of BRAF V600E has shown promise in overall improvement and progression-free survival of patients with advanced melanoma with the V600E mutation.
  • BRAF mutation testing has been suggested since its presence confers resistance to EGFR (cetuximab and panitumumab), when KRASis not mutated.

Result reported: Positive or Negative for V600E or V600K

Lincoln Labs BRAF Mutation Analysis offers:

  • Turnaround time of 7-10 days
  • Our highly qualified staff is accessible for any assistance regarding the tests.
  • Broad coverage by most private and public insurance.

Specimen Requirement:

  1. Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for BRAF mutation analysis.
  2. Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
  3. Presence of tumor cells in the sample must be assessed by a pathologist.
  4. Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provide by the pathologist.
  5. One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.

Test Code:

ICD 10 Code:81210- BRAF (Raf proto-oncogene, serine/threonone kinase) (eg, colon cancer, melanoma), gene analysis, V600E variant(s).


One thought on “BRAF Mutation Analysis in Colorectal Cancers and Melanomas

Leave a Reply

2 − two =